Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Operating Leases: 2019-2022

Historic Operating Leases for Aytu Biopharma (AYTU) over the last 2 years, with Mar 2022 value amounting to $2.4 million.

  • Aytu Biopharma's Operating Leases fell 36.40% to $2.4 million in Q1 2022 from the same period last year, while for Mar 2022 it was $2.4 million, marking a year-over-year decrease of 36.40%. This contributed to the annual value of $2.6 million for FY2021, which is 261.93% up from last year.
  • Latest data reveals that Aytu Biopharma reported Operating Leases of $2.4 million as of Q1 2022, which was down 11.41% from $2.7 million recorded in Q4 2021.
  • Aytu Biopharma's 5-year Operating Leases high stood at $3.8 million for Q1 2021, and its period low was $211,056 during Q4 2020.
  • Over the past 3 years, Aytu Biopharma's median Operating Leases value was $2.5 million (recorded in 2021), while the average stood at $1.9 million.
  • Per our database at Business Quant, Aytu Biopharma's Operating Leases tumbled by 43.72% in 2020 and then spiked by 1,186.86% in 2021.
  • Quarterly analysis of 4 years shows Aytu Biopharma's Operating Leases stood at $375,000 in 2019, then slumped by 43.72% to $211,056 in 2020, then skyrocketed by 1,186.86% to $2.7 million in 2021, then tumbled by 36.40% to $2.4 million in 2022.
  • Its last three reported values are $2.4 million in Q1 2022, $2.7 million for Q4 2021, and $2.8 million during Q3 2021.